Multifunctional drugs with different CNS targets for neuropsychiatric disorders

Journal of Neurochemistry

Volumn 99, Issue 4, 2006, Pages 1033-1048

  Van Der Schyf, Cornelis J ^a   Geldenhuys, Werner J ^b   Youdim, Moussa B H ^c  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Depressive illness; Lewy body disease; Parkinson's disease; Schizophrenia

Indexed keywords

1 (4 CHLOROPHENYL) 4,5 DIHYDRO 5 (4 PYRIDYL) 1H 1,2,3 TRIAZOLE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 1 INHIBITOR; DEFEROXAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIZOCILPINE; DONEPEZIL; ETHYL 5 AMINO 6,7,8,9 TETRAHYDRO 2 METHYL 4 PHENYLBENZOL [1,8] APHTHYRIDINE 3 CARBOXYLATE; FLUOXETINE; GALANTAMINE; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMATE TRANSPORTER; IRON CHELATE; ISTRADEFYLLINE; ITH 4012; JWS USC 75IX; LADOSTIGIL; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEFIRACETAM; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOPAMINE; RANITIDINE DERIVATIVE; RASAGILINE; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TACRINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDARABINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; AMNESIA; AMYOTROPHIC LATERAL SCLEROSIS; CANCER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEPRESSION; DRUG ACTIVITY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG STRUCTURE; HALLUCINATION; HUMAN; HUNTINGTON CHOREA; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; STROKE;

ANIMALS; BRAIN; BRAIN CHEMISTRY; BRAIN DISEASES; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; NEUROTRANSMITTER AGENTS; NOOTROPIC AGENTS; PSYCHOTROPIC DRUGS;

EID: 33750462391     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04141.x     Document Type: Review

References (140)

1. Abe Y., Aoyagi A., Hara T. et al. (2003) Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease. J. Pharmacol. Sci. 93, 95-105.
2. Akk G. and Steinbach J. H. (2005) Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site. J. Neurosci. 25, 1992-2001.
3. Allen D. D. and Geldenhuys W. J. (2006) Molecular modeling of blood-brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous system. Life Sci. 78, 1029-1033.
4. 2+ channel dual blockers with highly potent anti-ischemic effects. Bioorg. Med. Chem. Lett. 9, 2999-3002.
5. Arundine M. and Tymianski M. (2004) Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell. Mol. Life Sci. 61, 657-668.
6. Auvin S., Pignol B., Navet E. et al. (2004) Novel dual inhibitors of calpain and lipid peroxidation. Bioorg Med. Chem. Lett. 14, 3825-3828.
7. Avramovich Y., Amit T. and Youdim M. B. H. (2002) Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J. Biol. Chem. 277, 31466-31473.
8. Avramovich-Tirosh Y., Amit T., Zheng H. et al. (2006) Neurorescue and reduction of amyloid-β peptide by novel multi-functional brain permeable iron chelators and green tea polyphenol EGCG. Curr. Res. Alzheimer's Dis. in press.
9. Baranauskas G., Tkatch T. and Surmeier D. J. (1999) Delayed rectifier currents in rat globus pallidus neurons are attributable to Kv2.1 and 1 Kv3.1/3.2 K(+) channels. J. Neurosci. 19, 6394-6404.
10. Ben-Shachar D., Eshel G., Finberg J. P. et al. (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56, 1441-1444.
11. Ben-Shachar D., Eshel G., Riederer P. et al. (2002) Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease. Annal. Neurol. 32(Suppl.), S105-S110.
12. Ben-Shachar D., Kahana N., Kampel V. et al. (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46, 254-263.
13. Boot J., Cases M., Clark B. P. et al. (2005) Discovery and structure-activity relationships of novel selective norepinephrine and dual serotonin/norepinephrine reuptake inhibitors. Bioorg. Med. Chem. Lett. 15, 699-703.
14. Breitner J. C., Welsh K. A., Helms M. J. et al. (1995) Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging 16, 523-530.
15. Bunch L., Nielsen B., Jensen A. A. et al. (2006) Rational design and enantioselective synthesis of (1R,4S,5R,6S)-3-azabicyclo[3.3.0] octane-4,6-dicarboxylic acid - a novel inhibitor at human glutamate transporter subtypes 1, 2, and 3. J. Med. Chem. 49, 172-178.
16. Burgut F. T., Benaur M. and Hencliffe C. (2006) Late-life depression: a neuropsychiatric approach. Expert Rev. Neurother. 6, 65-72.
17. Buxbaum J. D., Cullen E. I. and Friedhoff L. T. (2002) Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. Front. Biosci. 1, 50-59.
18. 2A receptor antagonists. Neurology 61, S62-S68.
19. Chabrier P. E., Auguet M., Spinnewyn B. et al. (1999) BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective strategy. Proc. Natl Acad. Sci. USA 96, 10824-10829.
20. Chen J. F., Steyn S., Staal R. et al. (2002) 8-(3-Chlorostyryl) caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. J. Biol. Chem. 277, 36040-36044.
21. Chertkow Y., Weinreb O., Youdim M. B. et al. (2005) The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex. Int. J. Neuropsychopharmacol. 4, 287-296.
22. Chertkow Y., Weinreb O., Youdim M. B. et al. (2006) The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex. Int. J. Neuropsychopharmacol. 9, 287-296.
23. Christiaans J. A. M. and Timmerman H. (1996) Cardiovascular hybrid drugs: Combination of more than one pharmacological property in one single molecule. Eur. J. Pharm. Sci. 4, 1-22.
24. Chung K. F. and Adcock I. M. (2004) Combination therapy of long-acting beta2-adrenoceptor agonists and corticosteroids for asthma. Treat. Respir. Med. 3, 279-289.
25. Collins F. and Lile J. D. (1989) The role of dihydropyridine-sensitive voltage-gated calcium channels in potassium-mediated neuronal survival. Brain Res. 502, 99-108.
26. Cordle A. and Landreth G. (2005) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. J. Neurosci. 25, 299-307.
27. Crichton R. R., Wilmet S., Legssyer R. et al. (2002) Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J. Inorg. Biochem. 91, 9-18.
28. Cummings J. L. and Zhong K. (2006) Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Nat. Rev. Drug Discov. 5, 64-74.
29. Cunningham M. J. and Nathan D. G. (2005) New developments in iron chelators. Curr. Opin. Hematol. 12, 129-134.
30. 2+ signals and neurotransmitter release. Mol. Pharmacol. 64, 1217-1226.
31. Dall'Igna O. P., Porciuncula L. O., Souza D. O. et al. (2003) Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br. J. Pharmacol. 138, 1207-1209.
32. Dall'Igna O. P., Souza D. O. and Lara D. R. (2004) Caffeine as a neuroprotective adenosine receptor antagonist. Ann. Pharmacother. 38, 717-718.
33. Demerle-Pallardy C., Gillard-Roubert V., Marin J. G. et al. (2000) In vitro antioxidant neuroprotective activity of BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation. J. Neurochem. 74, 2079-2086.
34. Dengiz A. N. and Kershaw P. (2004) The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease. CNS Spectr. 9, 377-392.
35. Eisenstein R. S. (2000) Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu. Rev. Nutr. 20, 627-662.
36. Farlow M. R. (2004) NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease. Geriatrics 59, 22-27.
37. Fassbender K., Simons M., Bergmann C. et al. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 5856-5861.
38. Floden A. M. and Li S. (2005) Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J. Neurosci. 25, 2566-2575.
39. Francis P. T., Palmer A. M., Snape M. et al. (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiat. 66, 137-147.
40. Friedhoff L. T., Cullen E. I., Geoghagen N. S. et al. (2001) Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int. J. Neuropsychopharmacol. 4, 127-130.
41. FrishmanW. H. and Zuckerman A. L. (2004) Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. Expert Rev. Cardiovasc. Ther. 2, 675-781.
42. Furlan R., Kurne A., Bergami A. et al. (2004) A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. J. Neuroimmunol. 150, 10-19.
43. Gal S., Zheng H., Fridkin M. et al. (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases, II; in vivo selective brain monoamine oxidase inhibition and prevention of MPTP induced striatal dopamine depletion. J. Neurochem. 95, 79-88.
44. Geldenhuys W. J., Lockman P. R., Nguyen T. H. et al. (2005b) 3DQSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter. Bioorg. Med. Chem. 13, 4253-4261.
45. Geldenhuys W. J., Malan S. F., Bloomquist J. R. et al. (2005a) Pharmacology and structure-activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives. Med. Res. Rev. 25, 21-48.
46. Gerriets T., Stolz E., Walberer M. et al. (2003) Neuroprotective effects of MK-801 in different rat stroke models for permanent middle cerebral artery occlusion: adverse effects of hypothalamic damage and strategies for its avoidance. Stroke 34, 2234-2239.
47. Goodman C., Knoll G., Isakov V. et al. (2005) Negative attitude towards medication is associated with working memory impairment in schizophrenia patients. Int. Clin. Psychopharmacol. 20, 93-96.
48. Goruglu A., Kins T., Cobanoglu S. et al. (2000) Reduction of edema and infarction by memantine and MK-801 after focal cerebral ischemia and reperfusion in rat. Acta Neurochir. (Wien) 142, 1287-1292.
49. Green R. A., Odergren T. and Ashwood T. (2003) Animal models of stroke: do they have value for discovering neuroprotective agents? Trends Pharmacol. Sci. 24, 402-408.
50. Greenblatt H. M., Kryger G., Lewis T., Silman I. and Sussman J. L. (1999) Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 463, 321-326.
51. Grunblatt E., Mandel S., Berkuzki T. et al. (1999) Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. 14, 612-618.
52. Gurwitz J. H. (2004) Polypharmacy: a new paradigm for quality drug therapy in the elderly? Arch. Intern. Med. 164, 1957-1959.
53. + current in projecting neurons from the globus pallidus. J. Neurophysiol. 82, 1512-1528.
54. Hilditch-Maguire P., Trettel F., Passani L. A. et al. (2000) Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum. Mol. Genet. 9, 2789-2797.
55. Horn J. and Limburg M. (2001) Calcium antagonists for ischemic stroke a systematic review. Stroke 32, 570-576.
56. Horn J., de Haan R. J., Vermeulen M. et al. (2001) Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. Stroke 32, 2433-2438.
57. Jain K. K. (2000) Evaluation of memantine for neuroprotection in dementia. Expert Opin. Invest. Drugs 9, 1397-1406.
58. Jakowec M. W. and Petzinger G. M. (2004) 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates. Comp. Med. 54, 497-513.
59. Joho R. H., Ho C. S. and Marks G. A. (1999) Increased gamma- and decreased delta-oscillations in a mouse deficient for a potassium channel expressed in fast-spiking interneurons. J. Neurophysiol. 82, 1855-1864.
60. Kadaba P. K. (2003) Rational drug design and the discovery of the delta2-1,2,3-triazolines, a unique class of anticonvulsant and anti-ischemic agents. Curr. Med. Chem. 10, 2081-2108.
61. Kalaria R. N. and Ballard C. (2001) Stroke and cognition. Curr. Atheroscler. Rep. 3, 334-339.
62. Kalivendi S. V., Cunningham S., Kotamraju J. et al. (2004) Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J. Biol. Chem. 279, 15 240-15 247.
63. Kapkova P., Alptuzun V., Frey P. et al. (2006) Search for dual function inhibitors for Alzheimer's disease: Synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their Abeta fibril formation inhibition capacity. Bioorg. Med. Chem. 14, 472-478.
64. Kaur D., Yantiri F., Rajagopalan S., Kumar J. et al. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37, 899-909.
65. Keith C. T., Borisy A. A. and Stockwell B. R. (2005) Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 4, 71-78.
66. Kemp J. A. and McKernan R. M. (2002) NMDA receptor pathways as drug targets. Nat. Neurosci. 5, 1039-1042.
67. Kiewert C., Hartmann J., Stoll J. et al. (2006) NGP1-01 is a brain-permeable dual blocker of neuronal voltage- and ligand-operated calcium channels. Neurochem. Res. 31, 395-399.
68. Lipton P. (1999) Ischemic cell death in brain neurons. Physiol. Rev. 79, 1431-1568.
69. Maia L. and de Mendonca A. (2002) Does caffeine intake protect from Alzheimer's disease? Eur. J. Neurol. 9, 377-382.
70. Malan S. F., Van der Walt J. J. and Van der Schyf C. J. (2000) Structure-activity relationships of polycyclic aromatic amines with calcium channel blocking activity. Arch. Pharm. 333, 10-16.
71. 9,13]tridecane. Arch. Pharm. 336, 127-133.
72. Mandel S., Weinreb O. and Youdim M. B. H. (2003) Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs. Trends Pharmacol. Sci. 24, 184-191.
73. Mandel S., Maor G. and Youdim M. B. (2004) Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J. Mol. Neurosci. 24, 401-416.
74. McKenna M. T., Proctor G. R., Young L. C. et al. (1997) Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors. J. Med. Chem. 40, 3516-3523.
75. Mdzinarishvili A., Geldenhuys W. J., Abbruscato T. J. et al. (2005) NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia. Neurosci. Lett. 383, 49-53.
76. Meltzer H. Y., Li Z., Kaneda Y. et al. (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiat. 27, 1159-1172.
77. Menge T., Hartung H. P. and Stuve O. (2005) Opinion: Statins - a cure-all for the brain? Nat. Rev. Neurosci. 6, 325-331.
78. Moller H. J. (2005) Risperidone: a review. Expert Opin. Pharmacother. 6, 803-818.
79. Moriguchi S., Marszalec W., Zhao X. et al. (2004) Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons. J. Pharmacol. Exp. Ther. 310, 933-942.
80. Moriguchi S., Marszalec W., Zhao X. et al. (2005) Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons. J. Pharmacol. Exp. Ther. 307, 160-167.
81. Morphy R. and Rankovic Z. (2005) Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 48, 6523-6543.
82. Morphy R., Kay C. and Rankovic Z. (2004) From magic bullets to designed multiple ligands. Drug Discov. Today 9, 641-651.
83. Nan F., Bzdega T., Pshenichkin S. et al. (2000) Dual function glutamate-related ligands: discovery of a novel, potent inhibitor of glutamate carboxypeptidase II possessing mGluR3 agonist activity. J. Med. Chem. 43, 772-777.
84. Narahashi T., Moriguchi S., Zhao X. et al. (2004) Mechanisms of action of cognitive enhancers on neuroreceptors. Biol. Pharm. Bull. 27, 1701-1706.
85. Nicoletti F., Bruno V., Copani A. et al. (1996) Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci. 19, 267-271.
86. Nishizaki T., Matsuoka T., Nomura T. et al. (1998) Nefiracetam modulates acetylcholine receptor currents via two different signal transduction pathways. Mol. Pharmacol. 53, 1-5.
87. Nishizaki T., Matsuoka T., Nomura T. et al. (2000) Presynaptic nicotinic acetylcholine receptors as a functional target of nefiracetam in inducing a long-lasting facilitation of hippocampal neurotransmission. Alzheimer Dis. Assoc. Disord. 14, S82-S94.
88. + channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur. J., Pharmacol. 332, 121-131.
89. O'Shea R. D., Fodera M. V., Aprico K. et al. (2002) Evaluation of drugs acting at glutamate transporters in organotypic hippocampal cultures: new evidence on substrates and blockers in excitotoxicity. Neurochem. Res. 27, 5-13.
90. Oestreicher E., Sengstock G. J., Riederer P. et al. (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660, 8-18.
91. Orozco C., de Los Rios C., Arias E. et al. (2004) ITH4012 (ethyl 5-amino-6,7,8,9-tetrahydro-2-methyl-4-phenylbenzol[1,8] naphthyridine-3- carboxylate), a novel acetylcholinesterase inhibitor with 'calcium promotor' and neuroprotective properties. J. Pharmacol. Exp. Ther. 310, 987-994.
92. Ovbiagele B., Kidwell C. S., Starkman S. et al. (2003) Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke. Curr. Treat. Options Cardiovasc. Med. 5, 441-449.
93. Oyaizu M. and Narahashi T. (1999) Modulation of the neuronal nicotinic acetylcholine receptor-channel by the nootropic drug nefiracetam. Brain Res. 822, 72-79.
94. Pahan K., Sheikh F. G., Namboodiri A. M. et al. (1997) Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 100, 2671-2679.
95. Pantopoulos K. (2004) Iron metabolism and the IRE/IRP regulatory system: an update. Ann. N Y Acad. Sci. 1012, 1-13.
96. Parsons C. G., Danysz W. and Quack G. (1999) Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 38, 735-767.
97. 2A receptor antagonists. Bioorg. Med. Chem. 11, 1299-1310.
98. 2A receptors. Neurobiol. Aging 26, 957-964.
99. Rami A. and Krieglstein J. (1994) Neuronal protective effects of calcium antagonists in cerebral ischemia. Life Sci. 55, 2105-2113.
100. Ray S. K. and Banik N. L. (2003) Calpain and its involvement in the pathophysiology of CNS injuries and diseases: therapeutic potential of calpain inhibitors for prevention of neurodegeneration. Curr. Drug Targets CNS Neurol. Disord. 2, 173-189.
101. Reisberg B., Doody R., Stoffler A. et al. (2003) Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348, 1333-13341.
102. Rich J. B., Rasmusson D. X., Folstein M. F. et al. (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45, 51-55.
103. Riederer P., Danielczyk W. and Grunblatt E. (2004) Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology 25, 271-277.
104. Rodriguez-Franco M. I., Fernandez-Bachiller M. I., Perez C. et al. (2006) Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J. Med. Chem. 49, 459-462.
105. Rogers J. T. and Lahiri D. K. (2004) Metal and inflammatory targets for Alzheimer's disease. Curr. Drug Targets 5, 535-551.
106. Rogers J., Kirby L. C., Hempelman S. R. et al. (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology 43, 1609-1611.
107. Rogers J. T., Randall J. D., Cahill C. M. et al. (2002) An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 277, 45 518-45 528.
108. Roth B. L., Sheffler D. J. and Kroeze W. K. (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353-359.
109. Rutherford G. W., Sangani P. R. and Kennedy G. E. (2003) Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection. Cochrane Database Syst. Rev. 4, CD002037.
110. Sagi Y., Weinstock M. and Youdim M. B. H. (2003) Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J. Neurochem. 86, 290-297.
111. Sasaki T., Eguchi S. and Kiriyama T. (1971) A facial synthesis of monooxa and aza-cage compounds via transanullar cyclizations. Tetrahedron Lett. 2651-2654.
112. 5,9]undecan-3,6-dione system. Tetrahedron 30, 2707-2712.
113. Saura J., Luque J. M., Cesura A. M. et al. (1994) Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62, 15-30.
114. Schmitt B., Bernhardt T., Moeller H. J. et al. (2004) Combination therapy in Alzheimer's disease: a review of current evidence. CNS Drugs 18, 827-844.
115. Silver H. (2003) Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Int. Clin. Psychopharmacol. 18, 305-313.
116. Silver H. (2004) Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin. Pharmacother. 5, 2053-2058.
117. 2 receptor antagonism with potent serotonin reuptake inhibition. J. Med. Chem. 48, 6855-6869.
118. Snape M. F., Misra A., Murray T. K. et al. (1999) A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. Neuropharmacology 38, 181-193.
119. Sramek J. J. and Cutler N. R. (1999) Recent developments in the drug treatment of Alzheimer's disease. Drugs Aging 14, 359-373.
120. Sterling J., Herzig Y., Goren T. et al. (2002) Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem. 45, 5260-5279.
121. Temlett J. A., Landsberg J. P., Watt F. et al. (1994) Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J. Neurochem. 62, 134-146.
122. Terry A. V., Gattu M., Buccafusco J. J. et al. (1999) Ranitidine analog JWS-USC-75IX enhances memory related task performance in rats. Drug Dev. Res. 47, 97-106.
123. Toda N., Tago K., Marumoto S. et al. (2003) A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Bioorg. Med. Chem. 11, 4389-4415.
124. Van der Schyf C. J., Squier G. J. and Coetzee W. A. (1986) Characterization of NGP 1-01, an aromatic polycyclic amine, as a calcium antagonist. Pharmacol. Res. Commun. 18, 407-417.
125. Van Kooten F. and Koudstaal P. J. (1998) Epidemiology of post-stroke dementia. Haemostasis 28, 124-133.
126. 3H]MK-801 binding in rat cerebral cortex. Neurosci. Lett. 272, 21-24.
127. Weggen S., Eriksen J. L., Das P. et al. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216.
128. Wenk G. L., Rosi S., McGann K. et al. (2002) A nitric oxide-donating flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in the rat. Eur. J. Pharmacol. 453, 319-324.
129. Wilkinson D. and Murray J. (2001) Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int. J. Geriatr. Psychiat. 16, 852-857.
130. Youdim M. B. H. and Buccafusco J. J. (2005a) CNS Targets for multifunctional drugs in the treatment of Alzheimer's and Parkinson's diseases. J. Neural Transm. 112, 519-537.
131. Youdim M. B. H. and Buccafusco J. J. (2005b) Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 26, 27-35.
132. Youdim M. B. H., Stephenson G. and Ben-Shachar D. (2004) Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelator; a lesson from 6-hydroxopaime and iron chelators desferal and VK-28. Ann. N Y Acad. Sci. 1012, 306-325.
133. Youdim M. B. H., Bar Am. O., Yogev-Falach M. et al. (2005a) Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. 79, 172-179.
134. Youdim M. B. H., Fridkin M. and Zheng H. (2005b) Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech. Ageing Dev. 126, 317-326.
135. Zecca L., Youdim M. B., Riederer P. et al. (2004) Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5, 863-873.
136. Zerkak D. and Dougados M. (2004) Benefit/risk of combination therapies. Clin. Exp. Rheumatol. 5, S71-S76.
137. Zhao X., Yeh J. Z. and Narahashi T. (2001) Post-stroke dementia. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors. Ann. N Y Acad. Sci. 939, 179-186.
138. Zheng H., Gal S., Weiner L. M. et al. (2005a) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 95, 68-78.
139. Zheng H., Weiner L. M., Bar-Am. O. et al. (2005b) Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem. 13, 773-783.
140. Zou J. Y. and Crews F. T. (2005) TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res. 1034, 11-24.